• This record comes from PubMed

Oxime K203: a drug candidate for the treatment of tabun intoxication

. 2019 Mar ; 93 (3) : 673-691. [epub] 20181218

Language English Country Germany Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
18-01734S Czech Science Foundation - International
00179906 University Hospital Hradec Kralove - International
Long-term Development Plan Faculty of Military Health Sciences - International
SV/FVZ201601 Faculty of Military Health Sciences - International
2201/2018 Faculty of Science, University of Hradec Kralove - International

Links

PubMed 30564897
DOI 10.1007/s00204-018-2377-7
PII: 10.1007/s00204-018-2377-7
Knihovny.cz E-resources

For over 60 years, researchers across the world have sought to deal with poisoning by nerve agents, the most toxic and lethal chemical weapons. To date, there is no efficient causal antidote with sufficient effect. Every trialed compound fails to fulfil one or more criteria (e.g. reactivation potency, broad reactivation profile). In this recent contribution, we focused our attention to one of the promising compounds, namely the bis-pyridinium reactivator K203. The oxime K203 is very often cited as the best reactivator against tabun poisoning. Herein, we provide all the available literature data in comprehensive and critical review to address whether K203 could be considered as a new drug candidate against organophosphorus poisoning with the stress on tabun. We describe its development from the historical point of view and review all available in vitro as well as in vivo data to date. K203 is easily accessible by a relatively simple two-step synthesis. It is well accommodated in the enzyme active gorge of acetylcholinesterase providing suitable interactions for reactivation, as shown by molecular docking simulations. According to a literature survey, in vitro data for tabun-inhibited AChE are extraordinary. However, in vivo efficiency remains unconvincing. The K203 toxicity profile did not show any perturbations compared to clinically used standards; on the other hand versatility of K203 does not exceed currently available oximes. In summary, K203 does not seem to address current issues associated with the organophosphorus poisoning, especially the broad profile against all nerve agents. However, its reviewed efficacy entitles K203 to be considered as a backup or tentative replacement for obidoxime and trimedoxime, currently only available anti-tabun drugs.

References provided by Crossref.org

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...